Etude d’impact élargie sur la proposition de règlement relatif aux médicaments utilisés en pédiatrie[en] 

The paper draws the conclusion that the EU's new regulation on medicinal products for paediatric use will cost money to industry, government and consumer but will improve the health of children and, on balance, the gains will outweigh the losses.

This document was put together by Wija J. Oortwijn, Edwin Horlings, Silvia Anton, Mirjam van het Loo and James P. Kahan, can be downloaded from the RAND website .